Flow cytometry to detect Ps<sup>+</sup>CD41a<sup>-</sup>, Ps<sup>+</sup>CD41a<sup>-</sup>CD138<sup>+</sup>, Ps<sup>+</sup>CD41a<sup>-</sup>BCMA<sup>+</sup> microvesicles from bone marrow can be used to predict myeloma burden, furthermore, Ps<sup>+</sup>CD41a<sup>-</sup> microvesicles may as a potential index to MRD test. This evidence concerns the gene SDC1 and plasma cell myeloma.